Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of TCN-PM
(Triciribine) when administered as an approximately one-hour intravenous infusion on a weekly
schedule on days 1, 8 and 15 in a 28 day cycle in patients with advanced hematologic
malignancies;
To determine the pharmacokinetics (PK) of Triciribine following study drug administration.
Secondary objective:
To observe the anti-tumor effects of Triciribine, if any occur